{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:14:45Z","timestamp":1793042085665,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009865","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000}}],"reference-count":164,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009865.pub2","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:03:33Z","timestamp":1495411413000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Celecoxib for osteoarthritis"],"prefix":"10.1002","volume":"2017","author":[{"given":"Livia","family":"Puljak","sequence":"first","affiliation":[{"name":"University of Split School of Medicine; Cochrane Croatia; Soltanska 2 Split Croatia 21000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Marin","sequence":"additional","affiliation":[{"name":"Cochrane Croatia; Split Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davorka","family":"Vrdoljak","sequence":"additional","affiliation":[{"name":"School of Medicine in Split; Department of Family Medicine; Soltanska 2 Split Croatia 21000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Markotic","sequence":"additional","affiliation":[{"name":"University Clinical Hospital Mostar; Centre for Clinical Pharmacology; Kralja Tvrtka b.b. Mostar Bosnia and Herzegovina 88000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Utrobicic","sequence":"additional","affiliation":[{"name":"University of Split, School of Medicine; Central Medical Library; Soltanska 2 Split Croatia 21000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa; Department of Medicine; Ottawa ON Canada K1H 8M5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD009865.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/ijr.14.45","article-title":"Efficacy and tolerability of celecoxib in osteoarthritis patients who previously failed naproxen and ibuprofen: results from two trials","volume":"9","author":"Asmus","year":"2014","journal-title":"International Journal of Clinical Rheumatology"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Asmus MJ Essex MN Brown PB Mallen SR Efficacy and tolerability of celecoxib in patients with osteoarthritis who previously did not respond to or did not tolerate naproxen and ibuprofen: results from 2 identically designed randomized trials Osteoarthritis and Cartilage 2013 S253","DOI":"10.1016\/j.joca.2013.02.523"},{"issue":"6","key":"10.1002\/14651858.CD009865.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/ijr.14.45","article-title":"Efficacy and tolerability of celecoxib in osteoarthritis patients who previously failed naproxen and ibuprofen: results from two trials","volume":"9","author":"Asmus","year":"2014","journal-title":"International Journal of Clinical Rheumatology"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Asmus MJ Essex MN Brown PB Mallen SR Efficacy and tolerability of celecoxib in patients with osteoarthritis who previously did not respond to or did not tolerate naproxen and ibuprofen: results from 2 identically designed randomized trials Osteoarthritis and Cartilage 2013 S253","DOI":"10.1016\/j.joca.2013.02.523"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/74.11.1095","article-title":"Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial","volume":"74","author":"Bensen","year":"1999","journal-title":"Mayo Clinic Proceedings"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1592\/phco.19.16.1269.30879","article-title":"Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib","volume":"19","author":"Zhao","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/rheumatology\/kel296","article-title":"Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies","volume":"46","author":"Bingham","year":"2007","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.2009.107805","article-title":"Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice","volume":"69","author":"Moore","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/rheumatology\/kel296","article-title":"Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies","volume":"46","author":"Bingham","year":"2007","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.2009.107805","article-title":"Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice","volume":"69","author":"Moore","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1185\/030079906X80242","article-title":"Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies","volume":"22","author":"Birbara","year":"2006","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1185\/030079906X80242","article-title":"Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies","volume":"22","author":"Birbara","year":"2006","journal-title":"Current Medical Research and Opinion"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0013|cit13","first-page":"259","article-title":"Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies","volume":"10","author":"Boswell","year":"2008","journal-title":"Medscape Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0014|cit14","first-page":"259","article-title":"Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies","volume":"10","author":"Boswell","year":"2008","journal-title":"Medscape Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009865.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa052771","article-title":"Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis","volume":"354","author":"Clegg","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009865.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/ard.2009.120469","article-title":"Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT","volume":"69","author":"Sawitzke","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD009865.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/ket133","article-title":"A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis","volume":"52","author":"Conaghan","year":"2013","journal-title":"Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/03009740802419065","article-title":"A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis","volume":"38","author":"Dahlberg","year":"2009","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MJT.0b013e3181cec307","article-title":"Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and\/or hip: a double-blind, randomized, dose-ranging trial","volume":"18","author":"DeLemos","year":"2011","journal-title":"American Journal of Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clinthera.2008.01.016","article-title":"Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study","volume":"30","author":"Emery","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/147323001204000414","article-title":"Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial","volume":"40","author":"Essex","year":"2012","journal-title":"Journal of International Medical Research"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1177\/030006051204000623","article-title":"Response to nonsteroidal anti-inflammatory drugs in African Americans with osteoarthritis of the knee","volume":"40","author":"Essex","year":"2012","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/IJGM.S61297","article-title":"Efficacy and tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritis","volume":"7","author":"Essex","year":"2014","journal-title":"International Journal of General Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10067-005-1126-5","article-title":"Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib","volume":"25","author":"Fleischmann","year":"2005","journal-title":"Clinical Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1002\/art.11330","article-title":"Comparing the efficacy of cyclooxygenase 2\u2013specific inhibitors in treating osteoarthritis","volume":"48","author":"Gibofsky","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD009865.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1185\/03007995.2011.580340","article-title":"Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials","volume":"27","author":"Hochberg","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1002\/14651858.CD009865.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1185\/03007995.2011.580340","article-title":"Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials","volume":"27","author":"Hochberg","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1002\/14651858.CD009865.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/147323000102900602","article-title":"Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip","volume":"29","author":"Kivitz","year":"2001","journal-title":"Journal of International Medical Research"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1185\/030079905X38196","article-title":"Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib","volume":"21","author":"Lehmann","year":"2005","journal-title":"Current Medical Research and Opinion"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00124743-200106000-00004","article-title":"COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study","volume":"7","author":"McKenna","year":"2001","journal-title":"Journal of Clinical Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/030097401750065265","article-title":"Celecoxib versus diclofenac in the management of osteoarthritis of the knee: a placebo-controlled, randomised, double-blind comparison","volume":"30","author":"McKenna","year":"2001","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD009865.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/ard.2003.020313","article-title":"Patient preference for placebo, acetaminophen (paracetamol) or celecoxib efficacy studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis","volume":"63","author":"Pincus","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD009865.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/ard.2003.020313","article-title":"Patient preference for placebo, acetaminophen (paracetamol) or celecoxib efficacy studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis","volume":"63","author":"Pincus","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD009865.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/ard.2006.065128","article-title":"Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial","volume":"66","author":"Rother","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s10067-011-1776-4","article-title":"A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis","volume":"30","author":"Schnitzer","year":"2011","journal-title":"Clinical Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clinthera.2005.01.002","article-title":"Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo","volume":"27","author":"Sheldon","year":"2005","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0037|cit37","first-page":"611","article-title":"Long-term efficacy and safety of lumiracoxib 100 mg: an open-label extension of a 13-week randomized controlled trial in patients with primary osteoarthritis of the knee","volume":"26","author":"Sheldon","year":"2008","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD009865.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1185\/030079906X104876","article-title":"Rofecoxib 12.5 mg, rofecoxib 25 mg and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies","volume":"22","author":"Smugar","year":"2006","journal-title":"Current Medical Research and Opinion"},{"issue":"7","key":"10.1002\/14651858.CD009865.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1185\/030079906X104876","article-title":"Rofecoxib 12.5 mg, rofecoxib 25 mg and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies","volume":"22","author":"Smugar","year":"2006","journal-title":"Current Medical Research and Opinion"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archinte.165.2.161","article-title":"The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus","volume":"165","author":"Sowers","year":"2005","journal-title":"Archives of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/ard.2003.015974","article-title":"Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib","volume":"63","author":"Tannenbaum","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00124743-200004000-00002","article-title":"Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial","volume":"6","author":"Williams","year":"2000","journal-title":"Journal of Clinical Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0149-2918(01)80004-7","article-title":"Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee","volume":"23","author":"Williams","year":"2001","journal-title":"Clinical Therapeutics"},{"issue":"34","key":"10.1002\/14651858.CD009865.pub2-BIB0044|cit44","first-page":"1","article-title":"Clinical effects of Garcinia kola in knee osteoarthritis","volume":"3","author":"Adegbehingbe","year":"2008","journal-title":"Journal of Orthopaedic Surgery and Research"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0045|cit45","first-page":"511","article-title":"Celecoxib: a COX-2 inhibitor","volume":"5","author":"Andrews","year":"1999","journal-title":"American Journal of Managed Care"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11239-013-1035-4","article-title":"Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies","volume":"38","author":"Angiolillo","year":"2014","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"7-8","key":"10.1002\/14651858.CD009865.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1345\/aph.10382","article-title":"Upper gastroduodenal ulceration in arthritis patients treated with celecoxib","volume":"35","author":"Ashcroft","year":"2001","journal-title":"Annals of Pharmacotherapy"},{"issue":"9","key":"10.1002\/14651858.CD009865.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jpain.2004.09.004","article-title":"Pain management in osteoarthritis: A focus on onset of ef\ufb01cacy\u2014a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials","volume":"5","author":"Battisti","year":"2004","journal-title":"Journal of Pain"},{"issue":"Supp","key":"10.1002\/14651858.CD009865.pub2-BIB0049|cit49","first-page":"17","article-title":"Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience","volume":"60","author":"Bensen","year":"2000","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD009865.pub2-BIB0050|cit50","first-page":"1876","article-title":"Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo","volume":"27","author":"Bensen","year":"2000","journal-title":"Journal of Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009865.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003495-200363001-00006","article-title":"A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee","volume":"63","author":"Bianchi","year":"2003","journal-title":"Drugs"},{"issue":"8","key":"10.1002\/14651858.CD009865.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1742-1241.2007.01453.x","article-title":"Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib","volume":"61","author":"Bianchi","year":"2007","journal-title":"International Journal of Clinical Practice"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.joca.2008.04.009","article-title":"Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis","volume":"16","author":"Bingham","year":"2008","journal-title":"Osteoarthritis and Cartilage"},{"issue":"9","key":"10.1002\/14651858.CD009865.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1122\u20137","DOI":"10.1093\/rheumatology\/kep184","article-title":"Early response to COX-2 inhibitors as a predictor of overall responsein osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo","volume":"48","author":"Bingham","year":"2009","journal-title":"Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"352\u201361","DOI":"10.1111\/j.1526-4637.2011.01060.x","article-title":"Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo","volume":"12","author":"Bingham","year":"2011","journal-title":"Pain Medicine"},{"issue":"9","key":"10.1002\/14651858.CD009865.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3111\/13696998.2014.933111","article-title":"A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model","volume":"17","author":"Brereton","year":"2014","journal-title":"Journal of Medical Economics"},{"issue":"8","key":"10.1002\/14651858.CD009865.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/j.clinthera.2015.05.349","article-title":"Combined chondroitin sulfate and glucosamine versus celecoxib for painful knee osteoarthritis: Post-hoc analyses by Kellgren and Lawrence grade and C-reactive protein level from a randomized, double-blind, multicentre clinical trial","volume":"37","author":"Castgillo","year":"2015","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0058|cit58","first-page":"12","article-title":"Multicentric osteoarthritis intervention study with sysadoa (moves): Effects of combined glucosamine hydrochloride and chondroitin sulfate vs. celecoxib for painful knee osteoarthritis","volume":"115","author":"Castillo","year":"2014","journal-title":"Basic and Clinical Pharmacology and Toxicology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD009865.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/S0016-5085(15)30531-X","article-title":"Prevention of recurrent ulcer bleeding in arthritis patients with high cardiovascular and high gastrointestinal risks: A 18-month, double-blind, randomized trial","volume":"148","author":"Chan","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.joca.2004.11.002","article-title":"Celecoxib improves the efficiency of the locomotor mechanism in patients with knee osteoarthritis. A randomised, placebo, double-blind and cross-over trial","volume":"13","author":"Detrembleur","year":"2005","journal-title":"Osteoarthritis and Cartilage"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar2118","article-title":"Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis","volume":"9","author":"Dougados","year":"2007","journal-title":"Arthritis Research and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/ijr.13.71","article-title":"The efficacy of continuous versus intermittent celecoxib treatment in osteoarthritis patients aged < 60 and > 60 years","volume":"9","author":"Essex","year":"2014","journal-title":"International Journal of Clinical Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD009865.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.joca.2013.06.026","article-title":"The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial","volume":"21","author":"Gallelli","year":"2013","journal-title":"Osteoarthritis and Cartilage"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0065|cit64","first-page":"13","article-title":"Dexibuprofen in a special crystal form versus celecoxib in the management of osteoarthritis of the hip","volume":"152(Suppl 112)","author":"Hawel","year":"2002","journal-title":"Wiener Medizinische Wochenschrift"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0064|cit65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5414\/CPP41153","article-title":"Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip","volume":"41","author":"Hawel","year":"2003","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009865.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"A86","DOI":"10.1016\/j.joca.2015.02.788","article-title":"Combined chondroitin sulfate and glucosamine is more efficient than celebrex in reducing serum levels of Coll2-1, a cartilage degradation biomarker, in patients with severe OA: Results from a randomized, doubleblind, multicentric clinical trial","volume":"23","author":"Henrotin","year":"2015","journal-title":"Osteoarthritis and Cartilage"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1253\/circj.CJ-12-1573","article-title":"Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis","volume":"78","author":"Hirayama","year":"2014","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Hochberg M Martel-Pelletier J Monfort J Moller I Castillo JR Arden N Multicentric osteoarthritis intervention study with sysadoa (MOVES): Effects of combined glucosamine hydrochloride and chondroitin sulfate vs celecoxib for painful knee osteoarthritis Annals of the Rheumatic Diseases 2014","DOI":"10.1136\/annrheumdis-2014-eular.4950"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Hochberg MC Martel-Pelletier J Monfort J Moller I Du Souich P Pelletier JP Randomized, double-blind, multicenter, non inferiority clinical trial with combined glucosamine and chondroitin sulfate vs celecoxib for painful knee osteoarthritis Osteoarthritis and cartilage 2014","DOI":"10.1016\/j.joca.2014.02.069"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0070|cit70","first-page":"96","article-title":"Comparing celecoxib with traditional nonsteroidal anti-inflammatory drugs","volume":"52","author":"Johnson","year":"2003","journal-title":"Journal of Family Practice"},{"issue":"9","key":"10.1002\/14651858.CD009865.pub2-BIB0071|cit71","first-page":"1032","article-title":"Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib","volume":"33","author":"Leeb","year":"2004","journal-title":"Der Orthop\u00e4de"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ard.2006.052308","article-title":"A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip","volume":"66","author":"Luyten","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"S1","key":"10.1002\/14651858.CD009865.pub2-BIB0073|cit73","first-page":"S82","article-title":"Baseline predictors of improvement in pain using a pooled analysis of 7 randomized controlled studies in patients with osteoarthritis (OA)","volume":"13","author":"Moore","year":"2009","journal-title":"European Journal of Pain"},{"issue":"S1","key":"10.1002\/14651858.CD009865.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.joca.2016.01.114","article-title":"LY2951742, a monoclonal antibody against CGRP, failed to reduce signs and symptoms of knee osteoarthritis","volume":"24","author":"Jin","year":"2016","journal-title":"Osteoarthritis and Cartilage"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0075|cit75","unstructured":"NCT02192190 A study of LY2951742 in participants with mild to moderate osteoarthritis knee pain clinicaltrials.gov\/show\/NCT02192190"},{"issue":"S1","key":"10.1002\/14651858.CD009865.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.joca.2016.01.363","article-title":"Applications of Bayesian statistical methodology to success criteria: A case study of a phase 2 design with interim futility assessment in patients with knee osteoarthritis","volume":"24","author":"Smith","year":"2016","journal-title":"Osteoarthritis and Cartilage"},{"issue":"26","key":"10.1002\/14651858.CD009865.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0078|cit78","first-page":"263","article-title":"The efficacy and toleration of celecoxib (Celebrex) in the treatment of osteoarthritis in Nigeria: a multicentre study","volume":"24","author":"Ogunlade","year":"2005","journal-title":"West African Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0079|cit79","first-page":"137","article-title":"In vivo effect of celecoxib and tenoxicam on oxidant\/ anti-oxidant status of patients with knee osteoarthritis","volume":"35","author":"Ozgocmen","year":"2005","journal-title":"Annals of Clinical and Laboratory Science"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD009865.pub2-BIB0080|cit80","first-page":"S189\u2013S190","article-title":"In a two-year double-blind randomized controlled multicenter study, chondroitin sulfate was significantly superior to celecoxib at reducing cartilage loss with similar efficacy at reducing disease symptoms in knee osteoarthritis patients","volume":"24","author":"Pelletier","year":"2016","journal-title":"Osteoarthritis and Cartilage"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD009865.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.lpm.2007.08.016","article-title":"Changes in quality of life in patients with osteoarthritis treated with celecoxib: the Qualice study","volume":"37","author":"Rozenberg","year":"2008","journal-title":"Presse M\u00e9dicale"},{"issue":"1-2","key":"10.1002\/14651858.CD009865.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000318746","article-title":"Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritisand osteoarthritis in Japan","volume":"83","author":"Sakamoto","year":"2011","journal-title":"Digestion"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1475-2891-11-21","article-title":"A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin","volume":"11","author":"Sampalis","year":"2012","journal-title":"Nutrition Journal"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1874312901307010032","article-title":"The efficacy of continuous versus Intermittent celecoxib treatment in osteoarthritis patients with body mass index \u226530 and <30 kg\/m\u00b2","volume":"7","author":"Sands","year":"2013","journal-title":"Open Rheumatology Journal"},{"issue":"6","key":"10.1002\/14651858.CD009865.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/annrheumdis-2013-204905","article-title":"Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain","volume":"74","author":"Schnitzer","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD009865.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD009865.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","article-title":"Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects","volume":"41","author":"Simon","year":"1998","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/1874312901206010006","article-title":"Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: A mixed treatment comparison","volume":"6","author":"Stam","year":"2012","journal-title":"Open Rheumatology Journal"},{"issue":"5","key":"10.1002\/14651858.CD009865.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"592\u20135","DOI":"10.1093\/rheumatology\/keh121","article-title":"Celecoxib 200 mg q.d. is ef\ufb01cacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing","volume":"43","author":"Stengaard-Pedersen","year":"2004","journal-title":"Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD009865.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.3899\/jrheum.110636","article-title":"Treatment of osteoarthritis with continuous versus intermittent celecoxib","volume":"38","author":"Strand","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0091|cit91","first-page":"7","article-title":"Comparison of the efficacy of celecoxib and diclofenac sodium in the treatment of knee osteoarthritis","volume":"50","author":"Ta\u015fc\u0131o\u011flu","year":"2004","journal-title":"T\u00fcrkiye Fiziksel T\u0131p ve Rehabilitasyon Derne\u011fi"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD009865.pub2-BIB0092|cit92","article-title":"Pooled efficacy and safety from phase 3 controlled studies of tanezumab in patients with osteoarthritis","volume":"67","author":"Tive","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"13","key":"10.1002\/14651858.CD009865.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/ajhp\/61.13.1391","article-title":"Therapeutic interchange involving replacement of rofecoxib or celecoxibwith valdecoxib","volume":"61","author":"Tran","year":"2004","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/papr.12167","article-title":"Assessment of pain and activity using an electronic pain diary and actigraphy device in a randomized, placebo-controlled crossover trial of celecoxib in osteoarthritis of the knee","volume":"15","author":"Trudeau","year":"2015","journal-title":"Pain Practice"},{"issue":"5","key":"10.1002\/14651858.CD009865.pub2-BIB0095|cit95","first-page":"61","article-title":"Effectiveness and tolerance of celebrex in osteoarthrosis (data of a Russian study)","volume":"73","author":"Tsvetkova","year":"2001","journal-title":"Terapevticheskii Arkhiv"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/ar1854","article-title":"First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]","volume":"8","author":"Wittenberg","year":"2006","journal-title":"Arthritis Research and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0097|cit97","first-page":"355","article-title":"Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: alongitudinal study of 3639 patients in community practice","volume":"31","author":"Wolfe","year":"2004","journal-title":"Journal of Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009865.pub2-BIB0099|cit98","first-page":"128","article-title":"Etoricoxib in the treatment of Korean patients with osteoarthritis","volume":"17","author":"Yoo","year":"2014","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD009865.pub2-BIB0098|cit99","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1185\/03007995.2014.955169","article-title":"Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial","volume":"30","author":"Yoo","year":"2014","journal-title":"Current Medical Research and Opinion"},{"issue":"10","key":"10.1002\/14651858.CD009865.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00296-014-2964-8","article-title":"Efficacy and safety of PG201 (Layla) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study","volume":"34","author":"Yoo","year":"2014","journal-title":"Rheumatology International"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/1756-185X.12667","article-title":"Efficacy and safety of nonsteroidal anti-inflammatory drugs in Asian patients with knee osteoarthritis: summary of a randomized, placebo-controlled study","volume":"19","author":"Essex","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0102|cit102","unstructured":"EUCTR2005-002772-14-GB A 13-week, multicenter, randomized, double-blind, doubledummy, placebo-controlled, parallel group trial of lumiracoxib (COX189) 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib (200 mg o.d.) as a positive control http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2005-002772-14-GB"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0300060516673707","article-title":"Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial","volume":"45","author":"Gordo","year":"2017","journal-title":"J Int Med Res"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.amjmed.2013.02.037","article-title":"NSAIDs are associated with lower depression scores in patients with osteoarthritis","volume":"126","author":"Iyengar","year":"2013","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"M167","DOI":"10.1093\/gerona\/56.3.M167","article-title":"Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib","volume":"56","author":"Lisse","year":"2001","journal-title":"Journals of Gerontology. Series A, Biological Sciences and Medical Sciences"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0106|cit106","unstructured":"Mastbergen SC De Boer TN Huisman AM Polak AA Bijlsma JWJ Lafeber FPJG 9th World Congress of the International Cartilage Repair Society; 2010, Nov 26-29, Barcelona, Spain. 2010 46S"},{"issue":"S10","key":"10.1002\/14651858.CD009865.pub2-BIB0107|cit107","article-title":"Pharmaceutical Grade Chondroitin Sulfate Improves Knee Osteoarthritis Symptoms More Than Placebo and As Much As Celecoxib: Results of the Chondroitin Vs Celecoxib Vs Placebo Trial (CONCEPT)","volume":"68","author":"Reginster","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.amjmed.2005.09.054","article-title":"Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study","volume":"119","author":"Singh","year":"2006","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0109|cit109","unstructured":"EUCTR2011-005398-22-ES Clinical study comparing a new signle dose chewable tablet as treatment knee osteoarthritis with moderate to severe pain, compared to placebo and celecoxib apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-005398-22-ES"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0110|cit110","unstructured":"NCT01765296 Phase III study of CG100649 in osteoarthritis patients clinicaltrials.gov\/show\/NCT01765296"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0111|cit111","unstructured":"NCT01768520 Evaluation of the efficacy and safety of entelon tab. 150 mg in patients with osteoarthritis of knee clinicaltrials.gov\/ct2\/show\/NCT01768520"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0112|cit112","unstructured":"NCT02079727 Condrosulf vs celebrex vs placebo in the treatment of knee OA clinicaltrials.gov\/show\/NCT02079727"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006776.pub2","article-title":"Using alternative statistical formats for presenting risks and risk reductions","author":"Akl","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1063-4584(05)80101-3","article-title":"Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop","volume":"4","author":"Altman","year":"1996","journal-title":"Osteoarthritis Cartilage"},{"issue":"10","key":"10.1002\/14651858.CD009865.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3899\/jrheum.141440","article-title":"Optimal strategies for reporting pain in clinical trials and systematic reviews: recommendations from an OMERACT 12 workshop","volume":"42","author":"Busse","year":"2015","journal-title":"Journal or Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/014107680609900315","article-title":"Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis","volume":"99","author":"Caldwell","year":"2006","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta12110","article-title":"Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation","volume":"12","author":"Chen","year":"2008","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0118|cit118","volume-title":"Drug Class Review: Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs): Final Report Update 3","author":"Chou","year":"2006"},{"issue":"9894","key":"10.1002\/14651858.CD009865.pub2-BIB0119|cit119","first-page":"769\u201379","article-title":"Vascular and upper gastrointestinal eff ects of non-steroidal anti-infl ammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Emberson","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0120|cit120","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"issue":"6","key":"10.1002\/14651858.CD009865.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00296-011-2263-6","article-title":"A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity","volume":"32","author":"Conaghan","year":"2012","journal-title":"Rheumatology International"},{"issue":"7","key":"10.1002\/14651858.CD009865.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/annrheumdis-2013-204763","article-title":"The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10033","key":"10.1002\/14651858.CD009865.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(16)30002-2","article-title":"Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis","volume":"387","author":"Costa","year":"2016","journal-title":"Lancet"},{"issue":"7365","key":"10.1002\/14651858.CD009865.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","article-title":"Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials","volume":"325","author":"Deeks","year":"2002","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0126|cit126","unstructured":"Food Drug Administration Information for healthcare professionals: Celecoxib (marketed as Celebrex) www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124655.htm (accessed February 20, 2017)"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1370\/afm.516","article-title":"Randomized controlled trials: do they have external validity for patients with multiple comorbidities?","volume":"4","author":"Fortin","year":"2006","journal-title":"Annals of Family Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.2008.204","article-title":"Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study","volume":"85","author":"Fosb\u00f8l","year":"2009","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD009865.pub2-BIB0129|cit129","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003831","article-title":"Celecoxib for rheumatoid arthritis","author":"Garner","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0130|cit130","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005115","article-title":"Rofecoxib for osteoarthritis","author":"Garner","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"g213","DOI":"10.1136\/bmj.g213","article-title":"Improving, and auditing, access to clinical trial results","volume":"348","author":"Goldacre","year":"2014","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0132|cit132","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2014"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"277\u201394","DOI":"10.1046\/j.1526-4637.2003.03034.x","article-title":"The unequal burden of pain: confronting racial and ethnic disparities in pain","volume":"4","author":"Green","year":"2003","journal-title":"Pain Medicine"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistencies in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0135|cit135","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jclinepi.2016.01.002","article-title":"Extracting data from figures with software was faster, with higher inter-rater reliability than manual extraction","volume":"74","author":"Jelicic Kadic","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7384","key":"10.1002\/14651858.CD009865.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bmj.326.7384.334","article-title":"Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity","volume":"326","author":"J\u00fcni","year":"2003","journal-title":"British Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.berh.2006.05.002","article-title":"Osteoarthritis: rational approach to treating the individual","volume":"20","author":"J\u00fcni","year":"2006","journal-title":"Best Practice & Research. Clinical Rheumatology"},{"issue":"7553","key":"10.1002\/14651858.CD009865.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/ard.16.4.494","article-title":"Radiological assessment of osteo-arthrosis","volume":"16","author":"Kellgren","year":"1957","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0141|cit141","first-page":"MR000033. DOI:","article-title":"Industry sponsorship and research outcome","volume":"12","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","article-title":"Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies","volume":"8","author":"McGettigan","year":"2011","journal-title":"PLoS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-2036.2003.01454.x","article-title":"Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors","volume":"17","author":"Micklewright","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"R644","DOI":"10.1186\/ar1704","article-title":"Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports","volume":"7","author":"Moore","year":"2005","journal-title":"Arthritis Research and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD009865.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jclinepi.2008.08.002","article-title":"Systematic reviewers commonly contact study authors but do so with limited rigor","volume":"62","author":"Mullan","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"c3515","DOI":"10.1136\/bmj.c3515","article-title":"Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study","volume":"341","author":"N\u00fcesch","year":"2010","journal-title":"British Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD009865.pub2-BIB0147|cit147","first-page":"804","article-title":"A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs","volume":"29","author":"Ofman","year":"2002","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD009865.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.joca.2004.02.001","article-title":"OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited","volume":"12","author":"Pham","year":"2004","journal-title":"Osteoarthritis and Cartilage"},{"issue":"5","key":"10.1002\/14651858.CD009865.pub2-BIB0149|cit149","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007320.pub2","article-title":"Joint lavage for osteoarthritis of the knee","author":"Reichenbach","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0150|cit150","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"3","key":"10.1002\/14651858.CD009865.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"291\u20138","DOI":"10.1016\/S0304-3959(02)00306-8","article-title":"Racial\/ethnic differences in the experience of chronic pain","volume":"100","author":"Riley","year":"2002","journal-title":"Pain"},{"issue":"12","key":"10.1002\/14651858.CD009865.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jclinepi.2011.06.009","article-title":"Development of a framework to identify research gaps from systematic reviews","volume":"64","author":"Robinson","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD009865.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cgh.2007.03.011","article-title":"Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review","volume":"5","author":"Rostom","year":"2007","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD009865.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jclinepi.2012.07.009","article-title":"Development and pilot test of a process to identify research needs from a systematic review","volume":"66","author":"Saldanha","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0155|cit155","doi-asserted-by":"crossref","unstructured":"Rofecoxib (Vioxx) voluntarily withdrawn from market CMAJ 2004 1027 8","DOI":"10.1503\/cmaj.1041606"},{"issue":"1B","key":"10.1002\/14651858.CD009865.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"31S","DOI":"10.1016\/S0002-9343(98)00072-2","article-title":"Recent considerations in nonsteroidal anti-inflammatory drug gastropathy","volume":"105","author":"Singh","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009865.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1002\/14651858.CD009865.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","article-title":"Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis","volume":"117","author":"Solomon","year":"2008","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD009865.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"10","key":"10.1002\/14651858.CD009865.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jclinepi.2014.11.016","article-title":"Survey of Cochrane protocols found methods for data extraction from figures not mentioned or unclear","volume":"68","author":"Vucic","year":"2015","journal-title":"Journal of Clinical Epidemiology"},{"issue":"17","key":"10.1002\/14651858.CD009865.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis","volume":"96","author":"Warner","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9204","key":"10.1002\/14651858.CD009865.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(99)12031-2","article-title":"COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease","volume":"355","author":"Willoughby","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD009865.pub2-BIB0164|cit164","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009865","article-title":"Celecoxib for osteoarthritis","author":"Vrdoljak","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009865.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:34:02Z","timestamp":1786588442000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009865.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":164,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009865.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]}}}